Holen Sie sich die Stockscreener-App
3.525
0.14%
0.015
Schlusskurs vom Vortag:
$3.51
Offen:
$3.5
24-Stunden-Volumen:
737.62K
Relative Volume:
0.35
Marktkapitalisierung:
$426.83M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-6.7788
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+14.87%
1M Leistung:
+10.19%
6M Leistung:
+80.26%
1J Leistung:
+125.32%
1-Tages-Spanne:
$3.47
$3.6309
1-Wochen-Bereich:
$2.95
$3.74
52-Wochen-Spanne:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.525 | 425.02M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.61 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.65 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.07 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.40 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics Raises $20 Million in Equity Financing - TipRanks
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - marketscreener.com
Technical Analysis: Why is Aclaris Therapeutics Inc stock going upTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline - Investing.com Canada
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates - Investing.com Australia
Aclaris: Q4 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (NASDAQ: ACRS) outlines deep immunology pipeline and 2025 losses - Stock Titan
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - MarketBeat
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Aclaris Therapeutics (ACRS) narrows 2025 loss and details 2026 trial milestones - Stock Titan
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Aclaris Therapeutics Reports Positive Interim Phase 1a Results for ATI-052 and Advances Pipeline with Upcoming Trials and IND Application - Quiver Quantitative
Mouse hair regrows 93% in Aclaris alopecia study, 2025 loss shrinks - Stock Titan
Aclaris: Fourth Quarter Financial Overview - Bitget
Aclaris starts phase 1b trial of ATI-052 in asthma patients - Investing.com Australia
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - The Manila Times
Aclaris tests experimental asthma antibody in new human trial - Stock Titan
Aclaris Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Market Rankings: Whats the beta of Seacoast Banking Corporation of Florida stockJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Will Aclaris Therapeutics Inc. stock recover faster than peersWeekly Market Report & Community Driven Trade Alerts - mfd.ru
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris lines up February spotlight at major biotech investor conferences - MSN
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 - MarketBeat
Aclaris at Guggenheim Summit: Strategic Biotech Developments By Investing.com - Investing.com Nigeria
Aclaris at Guggenheim Summit: Strategic Biotech Developments - Investing.com
What’s the beta of Aclaris Therapeutics Inc. stock2025 Fundamental Recap & Long-Term Investment Growth Plans - mfd.ru
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):